A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls

NCT01663740 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Infections

Interventions

DRUG: Valganciclovir

Sponsor

Hoffmann-La Roche